Biopsy
Methodology & AI Transparency ⓘ
Biopsy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: A biopsy is a procedure that removes cells or tissue from your body.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM L23.2 for Biopsy clinical workups.
- 3 Typical cash cost range: Primary evaluation for Biopsy incorporates clinical dermatologic lesion in Biopsy (L23.2: morphology exam) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Biopsy: maintaining 25-Hydroxy Vitamin D in Biopsy (L23.2: & hs-CRP) within 25(OH)D 40–65 ng/mL (L23.2).
Ask our AI Specialists anything about Biopsy
What Is Biopsy?
A biopsy is a procedure that removes cells or tissue from your body. A doctor called a pathologist looks at the cells or tissue under a microscope to check for damage or disease. The pathologist may also do other tests on it. Biopsies can be done on all parts of the body. In most cases, a biopsy is the only test that can tell for sure if a suspicious area is cancer. But biopsies are performed for many other reasons too. There are different types of biopsies. A needle biopsy removes tissue with a needle passed through your skin to the site of the problem. Other kinds of biopsies may require surgery.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Biopsy (code L23.2) is keratinocyte hyperproliferation [Biopsy L23.2], Cross-referenced with NIH MeSH (Biopsy), which Dermatology: Acne, Eczema, Psoriasis & Rosacea clinicians address while surveilling 25-Hydroxy Vitamin D in Biopsy (L23.2: & hs-CRP) (25(OH)D 40–65 ng/mL (L23.2)).
Common Symptoms & Clinical Signs
- • Presentation of Biopsy (L23.2): post-inflammatory hyperpigmentation, facial in Biopsy (L23.2: flushing, or pitted)
- • Secondary Biopsy clinical sign: recurrent flares triggered in Biopsy (L23.2: by UV exposure,)
- • Symptom flares in Biopsy correlating with 25-Hydroxy Vitamin D in Biopsy (L23.2: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L23.2)
- • Functional skin & dermatology impact requiring clinical dermatologic lesion in Biopsy (L23.2: morphology exam) evaluation (L23.2)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Biopsy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L23.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Biopsy (L23.2: & hs-CRP) | 25(OH)D 40–65 ng/mL (L23.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Biopsy (L23.2: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L23.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Biopsy (L23.2: ALT (if systemic) | Within baseline reference limits (L23.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Biopsy
Treatment selection for Biopsy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Biopsy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Endometrial safety and tolerability of triphasic sequential hormone replacement: What a 341-Participant Study Found The triphasic E2V/MPA regimen was well tolerated and produced endometrial effects similar to those of the two comparators. Climacteric : the journal of the International Menopause Society • 2004-03-15 • Phase III Randomized Trial | N = 341 | 93/100 | PMID 15259280 ↗ |
| New Insights on Quantitative regression of qFibrosis with resmetirom: Exploratory histologic: What a 966-Participant Study Found Resmetirom treatment led to significant improvements in qFC, qFS, and individual collagen features associated with fibrosis progression. Journal of hepatology • 2026-08-15 • Phase III Randomized Trial | N = 966 | 93/100 | PMID 41895606 ↗ |
| New Insights on Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized: What a 1,284-Participant Study Found MUSIC-Screen will determine whether microUS can be used as an imaging modality to inform biopsy decision making that is non-inferior to mpMRI for GG ≥ 2 prostate cancer detection. Contemporary clinical trials • 2026-09-15 • Phase III Randomized Trial | N = 1,284 | 90/100 | PMID 42476253 ↗ |
| Can This Approach Help? Inside the Latest Research on Secukinumab Reduces Psoriasis-associated severe itching and Regenerates the SEC was superior to placebo by efficiently controlling reduced severe itching intensity, clinically normalizing skin lesions, and reversing histopathological abnormalities. Acta dermato-venereologica • 2024-11-20 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39565228 ↗ |
| Can This Approach Help? Inside the Latest Research on Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment In the main and OLE studies, PRO-C3/C3M (matrix metalloproteinase-degraded C3), a marker of net fibrosis formation, was reduced in resmetirom-treated patients (-0.76 [-1.27, -0.24], P = 0.0044 and -0.68, P Conclusion: The... Hepatology communications • 2021-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33860116 ↗ |
Biopsy Patient Community & “People Like Me” Threads
Filter Biopsy community threads and patient logs by age, biological sex, dosage, and treatment duration.